98%
921
2 minutes
20
Background: Major system reform is complex but can yield improved outcomes at multiple levels. We aimed to evaluate the impact of implementing a hub and spoke model of stroke care across metropolitan Adelaide (population 1.2 million), South Australia on mortality, morbidity, service and quality stroke indicators.
Methods: Analysis of 24 months of prospectively collected, patient-level data covering all metropolitan stroke admissions during the contiguous pre-, during- and post-implementation time periods, linked to mortality data from the National Death Index. The three metropolitan tertiary hospital-based stroke units undertook the implementation of a centralised 'hub and spoke' model: one central comprehensive stroke centre offering 24 h stroke reperfusion therapies, and two primary stroke centres providing 12 h thrombolysis. The main outcome measures were mortality (any cause) up to 180 days post-admission; reperfusion treatment proportions and timings; stroke care quality composite metric; length of stay.
Results: There were 3917 confirmed stroke admissions over the 24-month period (3325 (84.9%) ischaemic) and 650 deaths (19.6%) within 180 days. Compared to the baseline period, post-intervention mortality and discharge disability did not differ, although a possible temporary increase in ischaemic stroke mortality during implementation was seen. Rates of endovascular thrombectomy (EVT) (5.7% vs. 12.5%, adjusted Rate Ratio (aRR) = 1.94, 95%CI 1.21,3.10) and timeliness of EVT (median 126 min (IQR 83, 154) vs. 95 min (53, 132), p < 0.001) improved as did the composite stroke quality metric indicator (0.60, 95% CI 0.50, 0.70 vs. 0.64, 95% CI 0.50, 0.75; adjusted difference 0.041, 95% CI 0.015, 0.066). Length of stay decreased for ischaemic stroke (8.2 (SD 12.4) vs. 7.9 (SD 8.9) days, adjusted geometric mean ratio = 0.83, 95% CI 0.73. 0.94) but not for intracerebral haemorrhage.
Conclusion: The major implementation of a metropolitan centralised 'hub and spoke' model of acute stroke care was associated with overall significant improvements in process indicators but a possible temporary increase in ischaemic stroke mortality during implementation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403268 | PMC |
http://dx.doi.org/10.1186/s12913-025-13411-3 | DOI Listing |
J Cereb Blood Flow Metab
September 2025
Achucarro Basque Center for Neuroscience, Leioa, Spain.
Adenosine A receptors (AARs) have shown promising therapeutic properties despite their controversial role in modulating stroke outcome. However, the temporal evolution of cerebral AARs density after cerebral ischemia and its subsequent neuroinflammatory response have been scarcely explored. In this study, the expression of AARs after transient middle cerebral artery occlusion (MCAO) was evaluated in rats by positron emission tomography (PET) with [C]SCH442416 and immunohistochemistry (IHC).
View Article and Find Full Text PDFHum Brain Mapp
September 2025
Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Perinatal stroke is a vascular injury occurring early in life, often resulting in motor deficits (hemiplegic cerebral palsy/HCP). Comorbidities may also include poor neuropsychological outcomes, such as deficits in memory. Previous studies have used resting state functional MRI (fMRI) to demonstrate that functional connectivity (FC) within hippocampal circuits is associated with memory function in typically developing controls (TDC) and in adults after stroke, but this is unexplored in perinatal stroke.
View Article and Find Full Text PDFEur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Eur Stroke J
September 2025
Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Introduction: Randomised controlled trials comparing endovascular thrombectomy (EVT) to medical treatment in patients with medium vessel occlusion (MeVO) suggested neutrality or futility of EVT. We studied whether the size difference between thrombectomy device and the occluded vessel influenced MeVO outcomes.
Patients And Methods: This was a retrospective single-centre observational study comprising EVT-treated patients with occlusion of the M2 branch of the middle cerebral artery on digital subtraction angiography.
Eur Stroke J
September 2025
Department of Neurology & Stroke Center, University Hospital of Basel & University of Basel, Basel, Switzerland.
Introduction: Recent studies in stroke patients from predominantly Asian populations have underscored the significance of trimethylamine N-oxide (TMAO) as a valuable blood biomarker for predicting incident strokes and major adverse cardiovascular events (MACE). However, its prognostic role after ischemic stroke in other populations is not yet comprehensively investigated.
Patients And Methods: We measured plasma TMAO levels in 1726 acute ischemic stroke patients (within 24 h from symptom onset) from the multicenter BIOSIGNAL cohort.